MYCN and neuroblastoma: International and perhaps worldwide RCTs in patients having similar upfront treatments powered to look at individual subgroups (relapsed versus refractory, MYCN amplification status) are required to determine the ideal backbone upon which to test novel targeted agents to try and cure more children with relapsed high-risk neuroblastoma.